Document is current
Any future updates will be listed below
-
Authors
Dunger, David B.
Bruggraber, Sylvaine F. A.
Mander, Adrian P.
Marcovecchio, M. Loredana https://orcid.org/0000-0002-4415-316X
Tree, Timothy
Chmura, Piotr Jaroslaw
Knip, Mikael
Schulte, Anke M.
Mathieu, Chantal
,
Mathieu, C.
Gillard, P.
Casteels, K.
Overbergh, L.
Dunger, D.
Wallace, C.
Evans, M.
Thankamony, A.
Hendriks, E.
Bruggraber, S.
Peakman, M.
Tree, T.
Morgan, N.
Richardson, S.
Todd, J.
Wicker, L.
Mander, A.
Dayan, C.
Alhadj Ali, M.
Pieber, T.
Eizirik, D.
Cnop, M.
Brunak, S.
Pociot, F.
Johannesen, J.
Rossing, P.
Legido Quigley, C.
Mallone, R.
Scharfmann, R.
Boitard, C.
Knip, M.
Otonkoski, T.
Veijola, R.
Lahesmaa, R.
Oresic, M.
Toppari, J.
Danne, T.
Ziegler, A. G.
Achenbach, P.
Rodriguez-Calvo, T.
Solimena, M.
Bonifacio, E.
Speier, S.
Holl, R.
Dotta, F.
Chiarelli, F.
Marchetti, P.
Bosi, E.
Cianfarani, S.
Ciampalini, P.
de Beaufort, C.
Dahl-Jørgensen, K.
Skrivarhaug, T.
Joner, G.
Krogvold, L.
Jarosz-Chobot, P.
Battelino, T.
Thorens, B.
Gotthardt, M.
Roep, B.
Nikolic, T.
Zaldumbide, A.
Lernmark, A.
Lundgren, M.
Costecalde, G.
Strube, T.
Schulte, A.
Nitsche, A.
von Herrath, M.
Wesley, J.
Napolitano-Rosen, A.
Thomas, M.
Schloot, N.
Goldfine, A.
Waldron-Lynch, F.
Kompa, J.
Vedala, A.
Hartmann, N.
Nicolas, G.
van Rampelbergh, J.
Bovy, N.
Dutta, S.
Soderberg, J.
Ahmed, S.
Martin, F.
Agiostratidou, G.
Koralova, A.
Willemsen, R.
Smith, A.
Anand, B.
Puthi, V.
Zac-Varghese, S.
Datta, V.
Dias, R.
Sundaram, P.
Vaidya, B.
Patterson, C.
Owen, K.
Piel, B.
Heller, S.
Randell, T.
Gazis, T.
Bismuth Reismen, E.
Carel, J-C
Riveline, J-P
Gautier, J-F
Andreelli, F.
Travert, F.
Cosson, E.
Penfornis, A.
Petit, C.
Feve, B.
Lucidarme, N.
Cosson, E.
Beressi, J-P
Ajzenman, C.
Radu, A.
Greteau-Hamoumou, S.
Bibal, C.
Meissner, T.
Heidtmann, B.
Toni, S.
Rami-Merhar, B.
Eeckhout, B.
Peene, B.
Vantongerloo, N.
Maes, T.
Gommers, L.
Marcovecchio, M.L.
Vela, J.
Latres, E.
-
Funding
Funding for this research was provided by:
Innovative Medicines Initiative (115797, 945268)
- License Information
-
More Information
Article History
Received: 10 August 2021
Accepted: 30 March 2022
First Online: 18 May 2022
Declarations
:
: The INNODIA Clinical Trial Master Protocol was submitted to the European Medicines Agency Scientific Advice Working Party (SAWP) of the Committee for Medicinal Products for Human Use (CHMP) for Qualifications advice for novel methodologies in clinical drug development. A dossier was submitted and following written and face-to-face discussions with representatives from the SAWP, the final advice was received in February 2020 EMA/CHMP/SAWP/13547/2020.
: The authors declare that they have no competing interests.
